

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete If Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/778,002	
			Filing Date	02/11/2004	
			First Named Inventor	Birgit OPPMANN	
			Art Unit	<del>4640</del> 1649	
			Examiner Name	Hayes	
Sheet	1	of	3	Attorney Docket Number	DX0935KB

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
RH	AA	5,457,038A	10-10-1995	TRINCHIERI, et al.	
RH	AB	5,741,772A	04-21-1998	CHANG	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.*	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	†
		Country Code*Number*Kind Code* (if known)				
RH	AC	WO 98/33922A1	08-06-1998	CHANG, et al.		
↓	AD	WO 99/00415A1	01-07-1999	SHI, et al.		
	AE	WO 98/11225A2	03-19-1998	HILTON, et al.		
	AF	WO 98/31811A1	07-23-1998	DONALDSON, et al.		
	AG	WO 98/49307A1	11-05-1998	LOK, et al.		
	AH	WO 95/11303A1	4-27-1995	STAHL, et al.		
	AI	WO 99/20755A2	4-29-1999	ELSON, et al.		
	AJ	WO 99/28462A2	6-10-1999	WOOD, et al.		
	AK	WO 99/35264A1	7-15-1999	COSMAN, et al.		
	AL	WO 99/40195A1	8-12-1999	MATTSON, et al.		
	AM	EP 0759466A2	02-26-1997	GUBLER, et al.		
↓						

Examiner Signature	/Robert Hayes/	Date Considered	03/27/2007
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kin's Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.10 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/778,002	
			Filing Date	02/11/2004	
			First Named Inventor	Birgit OPPMANN	
			Art Unit	1646 1649	
			Examiner Name		
Sheet	2	of	3	Attorney Docket Number	DX0935KB

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
no	AN	BECHIARA, et al., "Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth," Cell, 83(2):313-322 (October 20, 1995).		
copies	AO	ELSON, et al., "Homo sapiens cytokine-like factor-1 precursor (CLF-1) mRNA, complete cds," GenBank, Accession No. AF059293 (August 2, 1998).		
in	AP	ELSON, et al., "Cytokine-Like factor-1, a novel soluble protein, shares homology with member of the cytokine type I receptor family," J. Immunol. 161(3):1371-1379 (August 1, 1998).		
parent	AQ	FISCHER, et al., "A bioactive designer cytokine for human hematopoietic progenitor cell expansion," Nat. Biotechnol., 15(2):142-145 (February 1997).		
	AR	GATELY, et al., "The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses" Annu. Rev. Immunol., 16:495-521 (1998).		
	AS	GOUGH, "Murine mRNA for leukaemia inhibitory factor (LIF)," GenBank, Accession Number X06381 (July 13, 1995).		
	AT	HABECKER, et al., "A sweat gland-derived differentiation activity acts through known cytokine signaling pathways" J. Biol. Chem. 272(48):30421-30428 (November 28, 1997).		
	AU	MCDONALD, "Human CNTF gene for ciliary neurotrophic factor," GenBank, Accession No. X60542 (August 16, 1991).		
	AV	PENNICA, et al., "Mus musculus cardiotrophin-1 mRNA, complete cds," GenBank, Accession No. U18368 (March 15, 1995).		
	AW	PENNICA, et al., "Human cardiotrophin-1 (CTF1) mRNA, complete cds," GenBank, Accession No. U43030 (January 9, 1996).		
RH	AX	PETERS, et al., "In vivo and in vitro activities of the gp130-stimulating designer cytokine hyper-IL-6," J. Immunol. 161(7):3575-3581 (October 1, 1998).		
RH	AY	RAKEMANN, et al., "The designer cytokine hyper-Interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro," J. Biol. Chem. 274(3):1257-1266 (January 1999).		
	AZ	SAOTOME, et al., "Mus musculus zinc finger protein (Pz1) mRNA, partial cds, and ciliary neurotrophic factor (Cntf) mRNA, complete cds," GenBank, Accession No. U05342 (November 29, 1995).		
Examiner Signature	/Robert Hayes/		Date Considered	03/27/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 806. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). ‡Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-796-9199) and select option 2.

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/778,002	
			Filing Date	02/11/2004	
			First Named Inventor	Birgit OPPMANN	
			Art Unit	1040	
			Examiner Name		
Sheet	3	of	3	Attorney Docket Number	DX0935KB

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>§</sup>
RH	BA	SENALDI, et al., "Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family," Proc. Natl. Acad. Sci. USA 96(20):11458-11463 (September 28, 1999).	
	BB	<del>SHELTON, "Are there more members of the CNTF-CRA family?" Persp. Devel. Neurobiol., 4(1):104-107 (1996).</del>	
RH	BC	SHI, et al. "Computational EST database analysis identifies a novel member of the neuropoietic cytokine family," Biochim. Biophys. Res. Commun., 262(1):132-138 (August 19, 1999).	
no	BD	<del>STAHL, et al., "Human leukemia inhibitory factor (LIF) gene, complete cds," GenBank Accession No. M63420 (October 31, 1994).</del>	
copies in	BE	<del>TRINCHIERI, "Proinflammatory and immunoregulatory functions of interleukin-12," Intern. Rev. Immunol. 16(3-4):365-396 (1998).</del>	
parent	BF	<del>WARE, et al., "Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death," Development 121(5):1283-1299 (May 1995).</del>	
	BG	<del>Database DGENE, Last updated 13-JUN-1999, Result from sequence search using SEQ ID NO:2, as the query and citing Accession Numbers: 98P-W94466, 98P-W56141, 98P-W29715, 98P-W56142, 98P-W26716, 97P-W29237, 96P-R88204, 95P-R83965; Derwent Information Ltd., London.</del>	
	BH	<del>Database DGENE, Last updated 13-JUN-1999, Result from sequence search using SEQ ID NO:12, as the query and citing Accession Numbers: 98P-W59805, 98P-W55012, 98P-W55011, 98P-W59804, 98P-W55014, 98P-W55015, 98P-W55016, 92P-R20934, 97P-W17859, 98P-R94576, 92P-R24273, 92P-R22228, 91P-R10795; Derwent Information Ltd., London.</del>	

Examiner Signature	/Robert Hayes/	Date Considered	03/27/2007
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-8199 (1-800-785-8199) and select option 2.